Keyron Medical Technology

Time to sign up for Health Wildcatters 2024 Pitch Day on 11/14! https://lnkd.in/g9wyXEpt

We're excited to announce that we've joined Health Wildcatters, one of the top healthtech accelerators in the US. Based in Dallas, their program aligns perfectly with our mission to make a real impact in the healthcare industry—and we're also proud of their investment into our company. We’re looking forward to leveraging the mentorship, resources, and investor network that Health Wildcatters provides as we continue developing transformative solutions for severe metabolic diseases. ✨ 🌐 Learn more at healthwildcatters.com #HealthWildcatters #Keyron #Accelerator #MedTech

Keyron Medical Technology is delighted to announce that our CEO, Dr Giorgio Castagneto Gissey, will be speaking at LSI Europe '24. He will present our impressive safety and efficacy data for the groundbreaking #ForePass EndoBypass Device, alongside details of our ongoing $10M+ Series A funding round. We look forward to seeing you there. 📅 September 16th - 20th 📍 Ritz-Carlton Hotel, Sintra, Portugal 🤝 If you're interested in discussing potential investment opportunities, please connect with Giorgio on LinkedIn or via email at gcgissey@keyron.com. 🌐 Learn more at keyron.com #Keyron #LSI #Healthcare #Medtech #Investment

Anticipation is building for next month's LSI Europe '24, with LSI Alumni leading the charge. Your 60-second news recap: Amsel Medical  → Announced the appointment of James A. Heinz, MSL as the new CEO. Arsenal Medical — Upma Sharma, PhD → Announced Late-Breaking Results from First-in-Human Clinical Trial of NeoCast™ Atraverse Medical, Inc. — John Slump → Announced the first clinical use of its HOTWIRE™ Radiofrequency (RF) Guidewire System at St. Bernards Medical Center. Axena Health — Jim O'Connor → Launched telehealth services for women seeking effective first-line incontinence treatment in collaboration with UpScript Health. Compliance Solutions (Life Sciences) Ltd — Edwin Lindsay → Announced the conditional acquisition of Compliance Solutions Life Sciences by Abingdon Health. Cyban Pty Ltd — Andrew Maxwell → Announced Steve Motes as the new Chief Strategy Officer for the US. Keyron Medical Technology — Giorgio Castagneto Gissey → Announced the successful completion of a preclinical study for its ForePass® Endoscopic Bypass System. Kneevoice Inc. — Gustavo De Greiff → Closed an oversubscribed Seed round of $1.2M led by NuFund Venture Group. LN Robotics — Jan Östman → Raised a ₩20 billion ($14.5 million) Series B funding round led by LB Investment, a leading venture capital firm in Korea. MedScout — Mark Mescher → Raised a $15M Series A funding round led by Fulcrum Equity Partners with continued support from existing investors, Stage 2, and LiveOak Ventures. MEXBRAIN — Thomas Brichart → Obtained clinical trial authorization for the treatment of ACLF in France. MOLLI Surgical — Ananth Ravi → Announced the company has been acquired by Stryker. Orchestra BioMed — David Hochman → Announced the appointment of John Mack to its Board of Directors. OUI Medical Inc — Dr Adarsh M Patil → Received FDA 510(k) clearance for its P-Scope Device. PK MED → Announced the appointment of LSI Alumni Yvonne Bokelman as Chairman of the Board of Directors. Protembis GmbH — Karl von Mangoldt → Received €20 million in venture-debt financing from the European Investment Bank (EIB) to support clinical trials, research and development, and market access programs for the ProtEmbo cerebral embolic protection system. Synchron — Thomas Oxley → Announced the world’s first-ever use of Apple Vision Pro, by one of the patients implanted with the Synchron brain computer interface. Tulavi Therapeutics — Josh Vose → Received de novo clearance from the FDA for an in situ forming hydrogel device designed to reduce the risk of neuroma formation in peripheral nerves post-amputation. WaveClear — Jeffrey Vaitekunas → Closed a $5 million Series AA financing round led by Botong Medical. WISE SpA — Luca Ravagnan → Raised a €25 million financing round, comprised of both equity investment and a venture debt loan from the European Investment Bank (EIB). Congratulations to all the LSI Alumni who made major news this week!

Keyron Announces ForePass® Preclinical Development Completion and Series A Investment Round Kick-Off Keyron Medical Technology is delighted to announce the completion of preclinical development for its ForePass® Endoscopic Bypass System, achieving several significant milestones in the process: ◉ Smooth and consistent 25-minute implants and 20-minute explants ◉ Excellent safety and tolerability, reporting no significant issues ◉ 3 times greater weight reduction than semaglutide ◉ 2 times greater efficacy on insulin resistance than gastric bypass surgery ◉ Data published in the highest-ranked peer-reviewed gastroenterology journal, Gut (BMJ) ◉ $3.2M invested by 10 top-notch KOLs and multiple VCs 📈 Upcoming Human Trials: We will now initiate the necessary preparatory work in view of our first in-human trials. Having mastered the technology and achieved industry-leading safety and efficacy in animal studies, our next big goal is to replicate these results and obtain top-of-the-class safety and efficacy data in humans. 💼 Series A Investment Round Kick-Off: We're excited to kick-off of our $10M+ Series A Investment Round. We have already secured $3M toward this round, which are committed by our shareholders alone. 📺 Stay tuned for more updates as we continue to push the boundaries of medical technology and deliver ground-breaking efficacy in treating #Diabetes, #MASH, #LiverFibrosis, and #Obesity. 🌐 Visit keyron.com for more information. #ForePass #Keyron #ClinicalTrials #MetabolicDiseases

Keyron Medical Technology are now poised for the final preparatory work leading up to their human trials for the ForePass® - an endoscopically implantable medical device designed not just to replicate but to surpass the unmatched metabolic benefits on weight loss, type 2 diabetes and liver disease typically associated with bariatric surgery - all without making a single cut to the digestive tract. #medtech #investment #milestone

Keyron Medical Technology is thrilled to announce a major milestone! We have just completed a highly successful preclinical study for our ForePass® Endoscopic Bypass System, and the results are truly groundbreaking: 🌟 Remarkable Safety and Tolerability: Our device demonstrated outstanding safety and tolerability in large animal models, setting a solid foundation for our upcoming human trials. 🌟 Exceptional Efficacy: The animals exhibited minimal weight gain of just 6 kg over 4 weeks, with a very low standard deviation. In stark contrast, controls gained more than 6 kg in just 1 week. 🌟 Impressive Results vs. Semaglutide: Our device resulted in a 3 times lower weight gain relative to Semaglutide, a blockbuster weight loss drug (GLP-1 receptor agonist) and the current standard of care. 🌟 Superior Impact on Insulin Resistance vs. Bariatric Surgery: In a previous study, ForePass® demonstrated a 2 times greater impact on insulin resistance (addressing diabetes, MASH, and liver fibrosis) compared to traditional gastric bypass surgery. ForePass® is an endoscopically implantable medical device designed not just to replicate but to surpass the unmatched metabolic benefits on weight loss, type 2 diabetes, and liver disease typically associated with bariatric surgery - all without requiring a single cut to the digestive tract. With the development of our device and delivery system now complete, we are poised for the final preparatory work leading up to our human trials. Stay tuned for more updates as we continue to advance the forefront of medical technology! 🌐 Visit keyron.com for more information #Innovation #Healthcare #Endoscopy #Keyron #ForePass #ClinicalTrials #Diabetes #Obesity #Liver

As we hit the #RoadToEurope we’re showcasing the innovators from around the globe who are selected to present at #LSIEurope24. Today we’re showcasing 3 innovators in the UK selected to present at LSI Europe ‘24 in Portugal: 1. Mary McGovern — Adtec Healthcare Limited → Its SteriPlas Cold Plasma device is a strong antibacterial solution with proven clinical efficacy for the management of chronic wounds, LVAD driveline infections, diabetic foot ulcers and deep sternal wound infections typically complicated with biofilm. 2. Giorgio Castagneto Gissey — Keyron Medical Technology → Focused on treating Type 2 diabetes, NASH, and obesity, in addition to other metabolic diseases. The company's ForePass device features an innovative design that enables a non-invasive bypass at the duodenal level. The device is inserted via endoscopy without requiring a single incision, thereby allowing the device to avoid the risks of traditional gastric bypass surgery. 3. Charles Nduka — emteq labs → Developing an emotional analytics platform intended to provide objective measurement of human responses in real time. The company's wearable solutions provide insights and measurements of emotional responses through biometric responses and facial muscle activity. We look forward to seeing these innovators take the stage this September 16th - 20th in Portugal. Want to see what other innovators are presenting at LSI Europe ‘24? Head over to our website to see the first 100+ innovators selected to present.

Keyron Medical Technology (#LSIEurope24 Innovator) is a Medtech company focused on treating Type 2 diabetes, NASH, and obesity, in addition to other metabolic diseases. Invented by one of the fathers of bariatric surgery, the company’s ForePass® system is a non-surgical solution that offers the benefits of surgery without any incisions. This technology is set to transform the treatment landscape for Type 2 Diabetes, MASH, and Severe Obesity. 🌟 Keyron has achieved many recent milestones including: • Its ForePass® system successfully reversed Type 2 Diabetes, MASH, Liver Fibrosis, and Obesity in animal studies, even surpassing the efficacy of traditional gastric bypass surgery for the first time by a medical device. • Achieved rapid deployment and retrieval within 30 minutes, ensuring long-term safety, tolerability, and remarkable efficacy. • Developed a robust portfolio with 16 patents fully granted, including in the U.S. and EU. • Raised $3M to date and is planning a $10M Series A to support its First-in-Human trial. We’re excited to welcome Dr. Giorgio Castagneto Gissey, CEO and Co-Founder of Keyron, to present at LSI Europe 2024 this September 16-20 in Sintra, Portugal. Join us in Portugal to meet with Giorgio and learn more about how Keyron is shaping the future of metabolic diseases.

Game changing medical device addressing a multi-billion market with a world-class team and offering an outstanding investment opportunity. Feel free to contact me if you would like to learn more.